Live Feeds
● LIVE Updated 1h ago · 9 sources tracked

Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree

Pharmaceutical company GSK expects its clinical cancer-drug pipeline to nearly double next year following an aggressive dealmaking spree. The growth signals that the company's strategic return to oncology research is beginning to yield tangible portfolio expansion. Executives and industry analysts point to recent clinical data supporting antibody-drug conjugates, known as ADCs, as phase 3 pushes ramp up. This progress follows a focused corporate effort to rebuild the drugmaker's cancer research and development footprint through targeted acquisitions and partnerships.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (9)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ GSK expects its cancer-drug clinical pipeline to nearly double in 2027 following a dealmaking spree.
🛡️ Source Corroboration: 9 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

GSK reported that its clinical cancer-drug pipeline is on track to nearly double in 2027 following recent dealmaking.

Live updates

  1. GSK Oncology Pipeline Set to Nearly Double After Deals

    Pharmaceutical company GSK expects its clinical cancer-drug pipeline to nearly double next year following an aggressive dealmaking spree. The growth signals that the company's strategic return to oncology research is beginning to yield tangible portfolio expansion. Executives and industry analysts point to recent clinical data supporting antibody-drug conjugates, known as ADCs, as phase 3 pushes ramp up. This progress follows a focused corporate effort to rebuild the drugmaker's cancer research and development footprint through targeted acquisitions and partnerships.

    Why it matters

    GSK previously shifted away from heavy oncology investments before reversing course to rebuild its pipeline through external dealmaking. The success of these newer therapeutic classes is crucial for replacing revenues from older blockbusters facing patent expirations. Investors are watching closely to see whether the expanded clinical portfolio will successfully translate into regulatory approvals and commercial returns.

    What is confirmed

    • GSK expects its cancer-drug clinical pipeline to nearly double in 2027 following a dealmaking spree.

    What to watch next

    • Progression of phase 3 trials for antibody-drug conjugates
    • Further announcements regarding clinical pipeline expansion in 2027
    Sources used for this update (10)
    1. www.snapchat.com — Benoit Chevalier (@benoitqueen) | Snapchat Stories ...
    2. flipboard.com — Beloved singer’s wife killed after welcoming robbery suspects with lemonade
    3. www.scmp.com — The EU’s China dilemma: how to counter Beijing without alienating friends | South China Morning Post
    4. WSJ — Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
    5. STAT — GSK sees its return to cancer start to pay off
    6. Quartz — GSK is expecting its cancer drug clinical pipeline to nearly double in 2027
    7. Fierce Biotech — ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
    8. Yahoo Finance — What Could GSK (LSE:GSK) Oncology Progress Mean For Investors?
    9. www.snapchat.com — Nicolas Vans (@nicolasvanst) | Snapchat Stories, Spotlight ...
    10. www.youtube.com — Emmerdale Full Episode | Tuesday 27th October 2026
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community